Wilmington Savings Fund Society FSB Invests $40,000 in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Wilmington Savings Fund Society FSB has made a new investment in Takeda Pharmaceutical Company Limited (NYSE:TAK) during the third quarter of 2024, according to recent reports by Holdings Channel. The institutional investor acquired 2,819 shares of Takeda's stock, which amounts to an investment valued at approximately $40,000.

Furthermore, several other hedge funds have also engaged in trading shares of Takeda Pharmaceutical. For instance, EverSource Wealth Advisors LLC increased its holdings in Takeda by 38.6% in the second quarter, resulting in ownership of 3,082 shares valued at roughly $43,000 after adding 859 shares in the last quarter. Similarly, BNP Paribas Financial Markets expanded its stake by a remarkable 416.0% during the third quarter, now owning 3,220 shares worth approximately $46,000 after acquiring an additional 2,596 shares.

In addition, Smithfield Trust Co boosted its holdings in Takeda by 76.9% in the third quarter, now possessing 3,428 shares valued at $49,000 after purchasing an extra 1,490 shares. Erste Asset Management GmbH entered a new investment in Takeda in the third quarter, valued at $52,000. Headlands Technologies LLC also acquired a new stake in the pharmaceutical company during the second quarter, with a value of $59,000. Presently, institutional investors and hedge funds collectively hold 9.17% of Takeda’s stock.

Current Performance of Takeda Pharmaceutical

As of the latest trading day, Takeda Pharmaceutical shares opened at $13.10. The company's financial indicators reveal a debt-to-equity ratio of 0.64, a quick ratio of 0.77, and a current ratio of 1.28. Over the past year, Takeda's stock has ranged between a low of $12.57 and a high of $15.08, with its 50-day moving average at $13.70 and a 200-day moving average at $13.88. Presently, the company has a market capitalization of $41.68 billion, a price-to-earnings (P/E) ratio of 22.59, and a PEG ratio of 0.25, along with a beta of 0.51.

Overview of Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited is actively involved in the research, development, manufacturing, marketing, and licensing of pharmaceutical products both in Japan and across international markets. The company offers a diverse range of pharmaceutical products that cover areas such as gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience.

investment, stocks, pharmaceutical